

# Toxicology Research

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

**1 Authors name:**

2 dr. Valeria Bellisario Ph.D.<sup>1</sup> M.S., dr. Giulio Mengozzi Ph.D. M.D.<sup>2</sup>, dr. Elena Grignani Ph.D.  
3 M.S.<sup>3</sup>, dr. Massimiliano Bugiani Ph.D. M.D.<sup>4</sup>, prof. Anna Sapino Ph.D. M.D.<sup>5</sup>, prof. Gianni  
4 Bussolati Ph.D. M.D.<sup>5</sup>, prof. Roberto Bono Ph.D. M.S.<sup>1\*</sup>

5

**6 Title:**

7 Towards a formalin-free hospital. Levels of 15-F<sub>2t</sub>-isoprostane and malondialdehyde to monitor  
8 exposure to formaldehyde in nurses from operating theatres.

9

**10 Affiliations**

11 <sup>1</sup> Department of Public Health and Pediatrics, University of Torino, Italy

12 <sup>2</sup> Clinical Chemistry Laboratory, San Giovanni Battista Hospital, Torino, Italy

13 <sup>3</sup> Salvatore Maugeri Foundation, Pavia, Italy

14 <sup>4</sup> Unit of Respiratory Medicine, National Health Service (ASL TO2), Turin, Italy

15 <sup>5</sup> Department of Medical Sciences, University of Turin, Turin, Italy

16

**17 Corresponding author contact:**

18 Roberto Bono. Department of Public Health and Pediatrics, University of Torino, Italy.

19 via Santena 5 bis. 10126 Torino, ITALY

20 roberto.bono@unito.it

21

**22 Acknowledgements:**

23 The authors wish to thank to Dr. Antonella Aloï and Dr. Antonio Cimino from A.U.O. Città della  
24 Salute e della Scienza, Torino, Italy, for the helpful technical and organizational support. This study  
25 was financially supported by a grant from the Office of Piedmont of the “Italian Institute for  
26 Insurance against Accidents at Work” (INAIL) to Roberto Bono.

27

**28 Keywords:**

29 15-F<sub>2t</sub>-Isoprostane, formaldehyde, malondialdehyde, oxidative stress, under vacuum sealing

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101

**Abstract:**

**Purpose:** Nurses are exposed to Formaldehyde when managing surgical samples to be later transferred to Histopathology. We evaluated conditions favouring the risk of exposure to this toxic reagent and the effect of measures to prevent it.

**Methods:** we conducted a cross-sectional study where 94 female workers were enrolled as potentially exposed to Formaldehyde. For each nurse were collected: 1) personal air-Formaldehyde by a personal dosimeter (8 hours); 2) a standardized questionnaire; 3) a urine sample to test 15-F<sub>2t</sub>-Isoprostane, Malondialdehyde, Cotinine.

**Results:** The results indicate a marked difference related to the adoption of the Under Vacuum Sealing procedure, as an alternative to Formaldehyde for preserving tissues. Nurses using the Under Vacuum Sealing system in the operating rooms are exposed to levels of Formaldehyde 75% lower than those who do not use that system. Oxidative stress biomarkers (15-F<sub>2t</sub>-Isoprostane, Malondialdehyde) are significantly higher in nurses using Formaldehyde ( $p < 0.001$ ) and in absence of Under Vacuum Sealing system ( $p = 0.027$ ), in particular in those workers that use liquid Formaldehyde in the operating theatre ( $p = 0.012$ ).

**Conclusions:** Analysis of biological biomarkers confirms a direct responsibility of air Formaldehyde on the onset of oxidative stress while the use of the Under Vacuum Sealing technique is associated with a significant reduction of the exposure to air- Formaldehyde and redox status. Our findings can be useful to characterize the environmental health risk in the operating theatres and to plan preventive measures such as the Under Vacuum Sealing procedure.

INTRODUCTION

Toxicology Research Accepted Manuscript

102 Formaldehyde (FA) is an important chemical widely used in many working environments including  
103 Hospitals <sup>1; 2; 3; 4; 5</sup>. Since FA represents an ubiquitous pollutant, breathable at variable levels in  
104 every living and working environment, the study of the relationship between exposure to this  
105 reagent, its biological effect and related diseases is important, but rather complex.

106 On the whole, exposure to FA is associated to a wide range of adverse health effects, from mild to  
107 severe <sup>6; 7</sup>. In particular, acute exposure to FA can cause irritation (on eyes, nose, throat, and skin),  
108 nasal congestion, sore throats, headaches, coughs, conjunctivitis, fatigue, rashes, shortness of  
109 breath, nausea and nosebleeds <sup>8; 9</sup>. FA is also known as a human carcinogen and as an inducer of  
110 chronic toxicity, being endowed with genotoxic and oxidant activity <sup>1; 10; 11; 12</sup>. Among the chronic  
111 effects of FA, an increased incidence of nasopharyngeal cancer in definite FA-exposed workers was  
112 demonstrated by some authors <sup>13; 14</sup> while others have shown a relationship between FA and  
113 leukemia <sup>15; 16</sup>.

114 Previous studies of our group already showed that FA, breathed in appropriate concentrations, is  
115 able to induce an oxidative imbalance <sup>17</sup>. To overcome and counteract this oxidative imbalance  
116 induced by FA, detoxifying enzymes are produced through different metabolic pathways <sup>18; 19</sup>. For  
117 example, F2-isoprostanes (F2-IsoPs) are prostaglandin-like bioactive compounds formed in vivo  
118 from the free radical-catalyzed peroxidation of essential fatty acids, like arachidonic acid. F2-IsoPs  
119 are stable and reliable molecules, detectable in all human tissues and biological fluids, including  
120 plasma, urine, fluid of broncho-alveolar lavage and cerebrospinal fluid. Based on their mechanism  
121 of synthesis, four F2-IsoP regioisomers (5-, 12-, 8-, or 15- series) may be generated, depending on  
122 which side of the chain the carbon atom is connected to. A F2-IsoP, produced abundantly in vivo  
123 and extensively tested for biological activity, is the 15-F2t-IsoP (8-iso-PGF2 $\alpha$ ), where "2t" is due to  
124 the trans position of the oriented side chain to the prostane ring <sup>20</sup>.

125 Recent studies stressed the usefulness of 15-F2t-IsoP to assess the oxidant stress in humans <sup>17; 21; 22;</sup>  
126 <sup>23</sup> but also to highlight pathological conditions <sup>24; 25</sup>. Since F2-IsoPs can be detected in urine  
127 specimen in a non invasive way, these molecules have been proposed as a suitable biomarker for  
128 oxidative stress <sup>12; 26</sup>. Another biomarker of lipid peroxidation is malondialdehyde (MDA), which is  
129 generated in vivo via peroxidation of polyunsaturated fatty acids and interacts with proteins, being  
130 itself potentially atherogenic <sup>18</sup>. Free radicals are able to activate the lipid peroxidation process in an  
131 organism and their increase causes an overproduction of MDA, which represents one of the final  
132 products of peroxidation of polyunsaturated fatty acids in the cells. MDA is commonly known as a  
133 biomarker of oxidative stress, but is also able to highlight the oxidative status in oncologic patients.  
134 Thus, data of epidemiological studies on humans support the significance of MDA as predictor of  
135 the imbalance in the oxidative stress status and lipid peroxidation. A recent paper of our group <sup>27</sup>

136 has shown that the histological process of tissue fixation in FA also implies an oxidative damaged  
137 of DNA as revealed by the formation of 3-(2-deoxy- $\beta$ -d-erythro-pentafuranosyl-pyrimido[1,2-  
138  $\alpha$ ]purin-10(3H)-one (M1dG). In particular, that paper showed that the percentage of M1dG adducts  
139 formed when the formalin-fixation procedures was adopted, was about 4-5 fold greater if compared  
140 to frozen tissues, which avoid the use of formaldehyde.

141 Interest on studies on the exposure of this toxic substance were, if possible, enhanced by the recent  
142 process leading to a formal banning of FA in the European countries in 2016, as a consequence of  
143 the EC Regulation n.605/2014 of 05.06.2014 that modifies the EC Regulation n.1272/2008. In some  
144 working processes, complete banning might be unattainable because of the lack of substitutes and  
145 specifically; thus, special exemptions for formalin use are going to be advanced. However, these  
146 requests should go in parallel with deeper knowledge of risk of exposure, while technical  
147 improvements and plans to reduce it to safe levels should be adopted.

148 In Healthcare, formalin is commonly used for fixing and preserving biologic specimens for  
149 pathologic and histologic examination or as a bactericide in embalming fluid and medical  
150 laboratories<sup>15</sup>. This practice is currently effected in two alternative ways, either by pouring liquid  
151 FA (3-5 litres) in large containers, or by using prefilled vials (containing 50-100 ml of FA). At  
152 variance to the use of FA, and with the specific goal of reducing exposure to this reagent, since a  
153 few years our Hospital adopted the practice of the Under-Vacuum Sealing (UVS) which involves  
154 the introduction of tissues removed by surgeons into a special plastic bag, afterwards placed under  
155 vacuum and chilled at + 4 °C until being transferred in the Pathology Laboratory.

156 The UVS procedure has potential for introducing some important improvements: a) it avoids the  
157 use of FA and the consequent human FA exposition in the operating rooms, b) keeps very well the  
158 anatomical and immunohistochemical features of tissues while reducing DNA damage, c) enhances  
159 the preservation of both structure and tissue components (proteins, nucleic acids), and, d) lengthens  
160 the useful time before the tissue fixation<sup>28,29</sup>. Moreover, tissues processed with UVS are suitable  
161 for tissue banking and cell culture<sup>30</sup>. Since the use of the UVS procedure in the Hospitals selected  
162 for this study was actually active only in some operating theatres, we intended to check if the  
163 adoption of this procedure implied objective differences in exposure to FA and variations in the  
164 related biological response. Specifically, we have assessed the intensity of oxidative stress and  
165 correlated it to the intensity of exposure to FA vapours.

166 To achieve this goal, we enrolled as volunteers a group of healthy female nurses, partly smokers,  
167 attending different operating theatres adopting or not the UVS system and making or not use of FA.  
168 Cohorts with different expositive scenarios have been compared with one another through the  
169 quantification of 15-F2t-IsoP and MDA as markers of lipid peroxidation, in order to assess

170 different FA exposures and the effectiveness of different tissue preservation procedures (UVS vs.  
171 FA). For each of the workers the exposure to tobacco smoke, a confounder because inducer of  
172 oxidative stress, was quantified using cotinine values as a marker.

173

## 174 METHODS

175 Study-subjects. Ninety-four female workers, recruited in the largest hospital of the Piedmont region  
176 in Italy (“Città della Salute e della Scienza” of Torino), were enrolled as subjects potentially  
177 exposed to FA in the operating theatre. In agreement with the standards of the institutional Ethical  
178 Committee on human experimentation and with the Helsinki declaration, all subjects were informed  
179 about the objectives of the study, and gave written, informed consent. Nurses, operating in surgical  
180 theatres, are traditionally exposed to FA because of the common and tradition practice of immersing  
181 in this preservative liquid (3-5 litres at a time) the surgical samples, of a size ranging between 2 and  
182 30 cm, to be later transferred to Pathology Lab. The preservation technique of which we want verify  
183 the effectiveness consists of introducing in special plastic bags the specimen removed by the  
184 surgeon and then inducing the complete removal of air from the plastic bag. UVS bags are then  
185 preserved at 4°C till transfer to the Pathology Lab. The 94 subjects, according to their professional  
186 involvement and exposition, were *a posteriori* grouped in 2 groups, the first composed of nurses  
187 working, on the day of sampling, in surgical theatres equipped with the apparatus (Tissue SAFE,  
188 Milestone, Bergamo, Italy) for the UVS procedure, the second group of nurses from theatres not  
189 engaged in this procedure and where the standard for all surgical specimens was the immersion in  
190 large containers where liquid FA (3-5 liters at a time) was poured.

191 In both type of theatres small biopsies (core or incisional) were immersed in vials (DiaPath,  
192 Bergamo, Italy) pre-filled with FA (50-100 ml) and sent to the Pathology Laboratory. Nurses from  
193 the first type of surgical theatres (UVS-equipped) were occasionally committed as well to the  
194 manage of liquid FA, for filling up containers for specimens / organs >30 cm in size, but most  
195 specimens (over 95%) were processed by UVS.

196 On Wednesday and Thursday, for each of 94 subjects, were collected the following items: 1) a  
197 personal air-FA sampling for one entire working shift (8 hours); 2) a standardized questionnaire; 3)  
198 an urine sample for the quantification of 15-F2t-IsoP, MDA, urinary cotinine and creatinine  
199 (CREA). A specimen of urine at the end of the working shift was collected from each volunteer and  
200 stored at -80 °C until analysis. On the whole, the only exclusion criteria was thus not to recruit  
201 males whereas all the females who have joined voluntarily in the study were included and recruited.

202 Personal Air-FA. FA air samples were collected for a working shift (8 hours) using passive,  
203 personal air samplers working with radial symmetry (Radiello®). The sampler was clipped near the

204 breathing zone of the subject to quantify as accurately as possible the air exposure during a work  
205 shift. Each sampler was equipped with a specific sorbent tube containing silica gel coated with 2,4-  
206 dinitrophenylhydrazine – DNPH – (NIOSH 2016). This last, reacting with FA, changes by  
207 derivatization to the 2,4-dinitrophenylhydrazone specific of FA derivative. Subsequently, the tube  
208 were quantified with a HPLC Perkin-Elmer equipped with an UV detector regulated at 360 nm <sup>31</sup>;  
209 <sup>32</sup>.

210 Questionnaire. On the same day of the personal air sampling, a questionnaire (a synthesis of the  
211 most extensive “GEIRD” questionnaire, [www.geird.org](http://www.geird.org)) was administered to all subjects by one  
212 interviewer obtaining information on individual, clinical features and smoking habits. Thus, the  
213 following individual and clinical information were acquired: age, sex, residence, hobbies, therapies,  
214 smoking habits, profession (qualifications, seniority, and job-specific work), use of FA in the  
215 operating theatre during the sampling day, and the presence and use of UVS system and  
216 environmental and personal devices to prevent FA exposure and health risks.

217 Urinary cotinine. Urinary cotinine was measured aiming to consider the possible role played by  
218 tobacco smoke in the onset of an oxidative stress status. An aliquot of fresh urine was collected in  
219 the morning and approximately at the same time from each volunteers, and stored at –80°C prior to  
220 analysis, performed within 20 working days. The enzyme immunoassay for cotinine is based on the  
221 competition between the cotinine in the urine sample and the cotinine-alkaline phosphatase  
222 conjugate: the sample containing the cotinine and the cotinine-alkaline phosphatase conjugate  
223 compete for binding to a limiting number of antibody sites. The bound enzymatic activity was  
224 measured by the addition of a chromogenic substrate. Therefore, the intensity of the color  
225 developed is inversely proportional to the concentration of cotinine in the sample. The  
226 concentration is calculated on the basis of a standard curve. The declared limit of detection is 1  
227 ng/ml.

228 Urinary isoprostane. 15-F2t-IsoP in urine was quantified by means of ELISA technique per-formed  
229 with a specific microplate kit, according to manufacturer’s instructions, (Oxford, MI, USA). 15-F2t  
230 IsoP in urine was measured by ELISA technique performed with a specific microplate kit (Oxford,  
231 MI, USA), according to manufacturer's instructions. 15-F2t-IsoP in the samples or standards  
232 competed with 15-F2t-IsoP conjugated to horseradish peroxidase (HRP) for binding to a polyclonal  
233 antibody specific for 15-F2t-IsoP coated on the microplate. The HRP activity resulted in color  
234 development when the substrate was added, with the intensity inversely proportional to the amount  
235 of unconjugated 15-F2t-IsoP in the samples or standards. The declared limit of detection is 0.2  
236 ng/ml. Dilution 1:4 was adopted to achieve better accuracy in the competitive ELISA method.  
237 Because of the high percentage of 15-F2t IsoP excreted in human urine conjugated to glucuronic

238 acid (over 50%), a preliminary incubation with  $\beta$ -glucuronidase for 2 h at 37 °C was performed, in  
239 order to detect the entire quantity of 15-F2t IsoP present in each urine sample.

240 Urinary malondialdehyde. A TBARS Assay kit (Abnova), according to manufacturer's instructions,  
241 measured MDA in urine. An aliquot of fresh urine was collected and stored at  $-80^{\circ}\text{C}$  prior to  
242 analysis performed within 20 days. Urine does not require any special treatments before analysis.  
243 The principle of the method is based on the reaction of a chromogenic reagent, 2-thiobarbituric  
244 acid, with MDA at  $25^{\circ}\text{C}$ . One molecule of MDA reacts with 2 molecules of 2-thiobarbituric acid  
245 with a Knoevenagel-type condensation to yield a chromophore with absorbance maximum at 532  
246 nm.

247 Creatinine quantification. In order to normalize the excretion rate of cotinine and 15-F2t-IsoP an  
248 aliquot of fresh urine was used to quantify the concentration of creatinine (CREA) by the kinetic  
249 Jaffé procedure.

250 Statistical analysis. Data were analyzed using STATA<sup>®</sup> vs 13.0 statistical package (StataCorp, Tex,  
251 USA). Appropriate linear transformations were applied on data whenever suggested by  
252 distributional diagnostic plots (symmetry plot, quantile plot) and descriptive statistic inspection  
253 (looking at variance stability among categories). A log-transformation was performed to find the  
254 power transformation that stabilize the variance and normalize the distribution. To compare the  
255 values among the resulted groups, a median test (non-parametric tests on the equality of medians)  
256 was applied, checking the null hypothesis that the K samples were drawn from populations with the  
257 same median.

258 Multiple Linear Regression (MLR) analysis with robust standard error estimate was used to analyze  
259 the relationship between log transformed personal air-FA ( $\mu\text{g}/\text{m}^3$ ) as dependent variable and use of  
260 UVS and the type of container of FA (prefilled or large container) as predictive variables and the  
261 relationship of log transformed 15-F2t- and MDA with the personal air-FA. The models were  
262 adjusted for cotinine, and age. For all tests, a  $p$  value of  $\leq 0.05$  (two-tailed) was considered  
263 significant. All the variables proving a significativity  $\geq 5\%$  were excluded

264

## 265 RESULTS

266 The 94 subjects, on the basis of the results of the questionnaire, were divided into 2 groups. The  
267 first group declared that he had worked the day of sampling in operating theatres equipped with the  
268 UVS device, the second group stated that he had worked in operating theatres without such device.  
269 In both type of theatres small biopsies (core or incisional) were immersed by nurses in vials pre-  
270 filled with FA (50-100 ml) and sent to the Pathology Laboratory. By studying the results of the  
271 questionnaires we observed that nurses from the first type of surgical theatres (UVS-equipped) were

272 occasionally committed as well to the manage of liquid FA, for filling up containers for specimens /  
273 organs >30 cm in size, but most specimens (over 95%) were processed by UVS.

274 **Table 1** describes the numerousness of groups of subjects who have used the FA during the  
275 sampling day according to the smoking habit. In the lower part of table 1, the subjects were also  
276 sub-grouped according to the availability of UVS in the operating theatres and, in both cases, to the  
277 epidemiological characteristics and smoking habits.

278 **Table 2** describes the personal air-FA concentrations ( $\mu\text{g}/\text{m}^3$ ), which came out to be higher in the  
279 64 subjects who used FA in the sampling day ( $p = 0.032$ ) and related to the use of the UVS  
280 technique ( $p = 0.040$ ) and to the use of FA (liquid or prefilled). The results indicate a significant  
281 difference related to the adoption of the UVS system when the FA was not used ( $p = 0.002$ ) but  
282 obviously even more so when the FA was used in liquid form ( $p = 0.001$ ) and not using prefilled  
283 vials. Furthermore, workers who use the liquid FA without UVS technique show overall an  
284 exposition to FA more than three times higher when compared to those who do not use this  
285 procedure.

286 For the further analysis, the FA concentrations were log-transformed to normalize the distribution  
287 and improve the homoscedasticity. Thus, the robust regression shows on one hand a concentration  
288 of air-FA, when adjusted by UVS use, directly proportional to the amount of FA used (liquid >  
289 prefilled) and, on the other hand a lower level of air-FA when UVS technique is adopted, with a  
290 significant interaction in the intensity of exposure to air-FA between use of FA and the adoption of  
291 UVS technique (**table 3**). Furthermore, given the significant interaction before mentioned, the effect  
292 of UVS is higher in subjects exposed to liquid FA than in those exposed to prefilled FA (coef. log -  
293 0.51 vs -0.15). Overall, results of the linear regression of FA shown in **figure 1**, underlines that the  
294 nurses who use the UVS system in the operating rooms are exposed to levels of FA 75% lower than  
295 those who do not use that system. Furthermore, as can be seen on the left side of the figure the  
296 adoption of the UVS allows halving the level of air-FA in the surgical theatre also in days when FA  
297 was not in use (no FA).

298 In the higher part of **table 4**, nurses who use FA show concentrations of 15-F2t-IsoP significantly  
299 higher if compared to not users of FA ( $p < 0.001$ ). The concentrations of 15-F2t-IsoP underline  
300 differences when the subjects are sub-grouped according to the adoption of the UVS procedure.  
301 Overall, 15-F2t-IsoP is higher in absence of UVS system ( $p = 0.027$ ) and, in particular, in those  
302 workers that use FA in the operating theatre without UVS ( $p = 0.029$ ). Besides, 15-F2t-IsoP levels  
303 are two times higher in subjects that used liquid FA in absence of UVS system ( $p = 0.012$ ). In the  
304 middle part of table 3 the concentrations of MDA are reported. The concentrations are significantly  
305 higher in subjects who use liquid FA and are not provided with UVS ( $p = 0.012$ ). Additionally, in

306 the lower part of table 3 the ability of cotinine to quantify effectively the intensity of exposure to  
307 tobacco smoke is confirmed in the present subjects, since a significantly higher level was observed  
308 in smokers ( $p = 0.035$ ) but this factor did not mask the use of different amounts of FA.

309 To deepen the positive relationship between FA exposure and synthesis of oxidative stress  
310 biomarkers, a multiple robust regression was calculated considering 15-F2t-IsoP, as the dependent  
311 variable, MDA, as a covariate, log-FA, UVS, urinary cotinine, age of subjects, and BMI as  
312 independent variables and confounding factors (**table 5**). After adjustment for UVS, cotinine, and  
313 age, findings show a positive and significant relationship between air-FA and oxidative stress  
314 biomarkers.

315

## 316 DISCUSSIONS

317 Since its introduction as a histological fixative back in the 19th century<sup>33</sup>, the 4% formaldehyde  
318 solution in water called Formalin has been adopted as the fixative of choice in histopathology.  
319 Besides its superior properties in guaranteeing structural preservation, FA fixation allows an  
320 immuno-histochemical and genetic definition of pathological lesions and this multi-faceted  
321 characterization carries paramount importance in planning therapies<sup>34</sup>. This implies that Health  
322 Authorities would object that dismissal of the use of FA would generate a major harm to the quality  
323 of diagnosis for patients.

324 FA is know to be toxic and is classified as a category 1B/2 carcinogen and a significant association  
325 was demonstrated between formalin-fixation procedures and the generation of oxidatively damaged  
326 DNA testified also by the formation of the molecular adduct M1dG<sup>27</sup>. This would justify its  
327 banning, as recently proposed by EU authorities. FA can induce increased levels of oxidative stress  
328 and enhanced formation of ROS by different ways, including the activation of oxidases and the  
329 inhibition of scavenger systems. For instance, FA is a substrate for the action of cytochrome P-450  
330 monooxygenase system II E1 isozyme and can be oxidized by peroxidase, aldehyde oxidase, and  
331 xanthine oxidase with subsequent ROS formation. However, given that to date a reagent able to  
332 guarantee the same performance in histopathology is not available, a reasonable policy is to reduce  
333 the risk, by creating working conditions in which the exposure of the personnel involved is limited  
334 to an acceptable minimum.

335 The present study shows that the adoption of the UVS procedure for the transfer of surgical  
336 specimens to the Pathology labs results in a sharp decline of exposure of nurses to FA. In fact, we  
337 give evidence of reduction of oxidative stress in nurses adopting the UVS technique as an  
338 alternative to the use of FA in operating theatres. This aspect has to be added to those already  
339 acquired, consisting of the approval of this procedure by pathologists who see improved their

340 chances of diagnosis and research, and in the greater facility with which the nursing staff can  
341 operate <sup>29</sup>.

342 The present study indicates that the major source of exposure to FA is not its use in pre-filled vials  
343 for fixing small biopsies, since in fact this procedure was carried out in both types of surgical  
344 theatres, while the bulk of exposure is related to the habit of pouring liquid FA (3-5 litres at a time)  
345 in large containers. In fact, the volunteers enrolled for this study who used the FA in liquid form  
346 showed a significantly higher exposure to FA than those who have not used it. Moreover, in  
347 preventive terms, the use of FA prefilled and, even more the use of the technique UVS, shows a  
348 significant reduction of the exposure to air-FA. Furthermore, the use of UVS technique fosters a  
349 lower level of air-FA as compared to that of theatres not equipped with the UVS apparatus, thus  
350 demonstrating a long-term "environmental efficiency" of UVS.

351 The more macroscopic effect of UVS technique is anyway observable when the FA is currently  
352 used in liquid form, since its breathable concentration is, in surgical theatres not equipped with  
353 UVS, 3 times higher. The robust regression (table 3) confirms a significant and independent  
354 interaction of air-FA exposition and UVS technique, underlining that the human intake of FA  
355 increases both as a result of use of a higher amount of FA and by the unavailability of the UVS  
356 technique. The linear regression of air-FA sub-grouped according by the UVS use and adjusted by  
357 cotinine and BMI highlighted in figure 1, allowed us to observe a greater effectiveness (-75%) of  
358 UVS technique on air-FA levels. In particular, these findings were evident among those who use the  
359 FA liquid than the FA in prefilled vials (table 3).

360 Analysis of biological oxidative stress biomarkers confirms a direct responsibility of air FA on the  
361 onset of oxidative stress. 15-F2t-IsoP is synthesized in significantly higher quantity when FA is  
362 used, in theatres where the UVS technique is not available, and when, without UVS, FA is used in  
363 liquid form. MDA seems to respond in a less sensitive way, proving to be significantly higher only  
364 when nurses are exposed to liquid FA that is to say to FA at higher concentrations. This aspect may  
365 depend on the biochemical characteristics of MDA, sensitive to FA in direct way, but most easily  
366 degradable, especially in the case of healthy subjects exposed in spot form. Thus, in future studies  
367 we believe that the measure of 15-F2t-IsoP is largely sufficient to quantify the extent of oxidative  
368 stress in the populations occupationally or environmentally exposed to formaldehyde.

369 In this study, cotinine was confirmed as a very sensitive and specific internal dose marker of  
370 smoking habits, able to exclude a role of this confounding factor among the subpopulations studied.

371 In fact, cotinine is a metabolite of nicotine and nicotine is a chemical present only in the tobacco  
372 leaves. Finally, a definitive evidence of the direct relationship between exposure to air-FA and  
373 increase of oxidative stress is provided by the robust multiple regression that describes this

374 relationship for 15-F2t-IsoP and MDA (table 5), after adjustment for use of the UVS technique,  
375 exposure to smoking and age.

376 The principal finding of this paper is to underline the preventive role of adoption of the UVS  
377 system, bound to eliminate exposure to formalin in the operating rooms. Thus, the adoption of the  
378 UVS procedure appears to offer both, environmental and technical advantages. In fact, on the one  
379 hand pathologists declare themselves largely satisfied for the histological characteristics of the  
380 tissues preserved under vacuum at +4 °C and, on the other hand, our results highlight drastic  
381 reduction of workers' exposure to airborne FA, both in environmental and biological terms. This  
382 indicates that adoption of the UVS procedure lead to the elimination of the FA in operating rooms  
383 and a significant reduction of FA in pathology departments receiving the tissues.

384 Our findings can be useful to characterize the risk in terms of imbalance of redox status,  
385 experienced from the subjects working in the operating theatre engaged or not in the UVS  
386 procedure. However, predictive role of the biomarkers of early biological effects are quite limited to  
387 assess individual risk. This is because the complex processes that lead from the exposure to the  
388 formalin to diseases are affected by many factors, many of which are still unknown or whose real  
389 impact is not estimable (e.g., individual genetic profile, age, life and working style, health status,  
390 etc.).

391 In conclusion, given that complete elimination of FA from the Health Care System could hardly be  
392 adopted since it would impact on the quality of diagnosis for patients, reduction of exposure seems  
393 a reasonable compromise. The present study demonstrates that preventive measures can be effective  
394 and the behaviour of the oxidative stress biomarkers highlights the feasibility of this approach. The  
395 crucial preventive role of the adoption of the UVS technique in the operating theatres <sup>27</sup>; <sup>35</sup> is here  
396 demonstrated.

397

#### 398 **COMPLIANCE WITH ETHICAL STANDARDS**

399 The study was submitted to the competent Ethics Committee of the "Azienda Ospedaliera Città della Salute e della  
400 Scienza" of Torino that approved the study (prot. 0071900, 25.6.2013 and prot. 0094007, 09/05/2013).

401 The manuscript does not contain report on clinical studies. The enrolled subjects are healthy adults who have voluntary  
402 participated in the study. Informed consent was obtained before the study from all individual participants included in  
403 the study. The study was conducted in accordance with the 1964 Helsinki declaration and its later amendments, all the  
404 data were treated anonymously and all the biological samples were destroyed after measurements.  
405

#### 406 **FUNDING**

407 This study was financially supported by a grant from the Office of Piedmont of the Italian Institute for Insurance against  
408 Accidents at Work (INAIL) to Roberto Bono for the years 2013 - 2015. The funding source had no role in the  
409 execution, interpretation and writing of the manuscript.  
410

#### 411 **CONFLICT OF INTEREST**

412 All authors declare that they have no conflict of interest  
413

414

#### 415 **REFERENCES**

- 416 1 Committee to Review the Formaldehyde Assessment in the National Toxicology Program 12th Report on  
417 Carcinogens, Board on Environmental Studies and Toxicology, Division on Earth and Life Sciences and National  
418 Research Council, *Review of the Formaldehyde Assessment in the National Toxicology Program 12th Report on*  
419 *Carcinogens*, National Academies Press (US), Washington (DC), 2014.
- 420 2 H. M. Bolt, G. H. Degen and J. G. Hengstler, *Arch. Toxicol.*, 2010, **84**, 421–422.
- 421 3 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, *IARC Monogr. Eval. Carcinog. Risks*  
422 *Hum. World Health Organ. Int. Agency Res. Cancer*, 2012, **100**, 9–562.
- 423 4 R. Bono, V. Bellisario, V. Romanazzi, V. Pirro, P. Piccioni, M. Pazzi, M. Bugiani and M. Vincenti, *Int. J. Hyg.*  
424 *Environ. Health*, 2014, **217**, 287–293.
- 425 5 R. Bono and V. Romanazzi, in *General Methods in Biomarker Research and their Applications*, eds. V. R. Preedy  
426 and V. B. Patel, Springer Netherlands, 2015, pp. 383–404.
- 427 6 M. Hulin, D. Caillaud and I. Annesi-Maesano, *Indoor Air*, 2010, **20**, 502–514.
- 428 7 M. Hulin, M. Simoni, G. Viegi and I. Annesi-Maesano, *Eur. Respir. J.*, 2012, **40**, 1033–1045.
- 429 8 R. Dales and M. Raizenne, *J. Asthma Off. J. Assoc. Care Asthma*, 2004, **41**, 259–270.
- 430 9 J. H. E. Arts, M. A. J. Rennen and C. de Heer, *Regul. Toxicol. Pharmacol. RTP*, 2006, **44**, 144–160.
- 431 10 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, *IARC Monogr. Eval. Carcinog. Risks*  
432 *Hum. World Health Organ. Int. Agency Res. Cancer*, 2006, **88**, 1–478.
- 433 11 O. Schmid and G. Speit, *Mutagenesis*, 2007, **22**, 69–74.
- 434 12 V. Romanazzi, V. Pirro, V. Bellisario, G. Mengozzi, M. Peluso, M. Pazzi, M. Bugiani, G. Verlato and R. Bono, *Sci.*  
435 *Total Environ.*, 2013, **442**, 20–25.
- 436 13 S. Duhayon, P. Hoet, G. Van Maele-Fabry and D. Lison, *Int. Arch. Occup. Environ. Health*, 2008, **81**, 695–710.
- 437 14 M. Hauptmann, J. H. Lubin, P. A. Stewart, R. B. Hayes and A. Blair, *Am. J. Epidemiol.*, 2004, **159**, 1117–1130.
- 438 15 L. Zhang, C. Steinmaus, D. A. Eastmond, X. K. Xin and M. T. Smith, *Mutat. Res.*, 2009, **681**, 150–168.
- 439 16 L. Zhang, L. E. B. Freeman, J. Nakamura, S. S. Hecht, J. J. Vandenberg, M. T. Smith and B. R. Sonawane, *Environ.*  
440 *Mol. Mutagen.*, 2010, **51**, 181–191.
- 441 17 R. Bono, V. Romanazzi, A. Munnia, S. Piro, A. Allione, F. Ricceri, S. Guarrera, C. Pignata, G. Matullo, P. Wang, R.  
442 W. Giese and M. Peluso, *Chem. Res. Toxicol.*, 2010, **23**, 1342–1348.
- 443 18 K. Uchida, *Free Radic. Biol. Med.*, 2000, **28**, 1685–1696.
- 444 19 C. Kum, F. Kiral, S. Sekkin, K. Seyrek and M. Boyacioglu, *Exp. Anim. Jpn. Assoc. Lab. Anim. Sci.*, 2007, **56**, 35–  
445 42.
- 446 20 L. J. Roberts and G. L. Milne, *J. Lipid Res.*, 2009, **50 Suppl**, S219–223.
- 447 21 H. Mitsumoto, R. M. Santella, X. Liu, M. Bogdanov, J. Zipprich, H.-C. Wu, J. Mahata, M. Kilty, K. Bednarz, D.  
448 Bell, P. H. Gordon, M. Hornig, M. Mehrazin, A. Naini, M. Flint Beal and P. Factor-Litvak, *Amyotroph. Lateral*  
449 *Scler. Off. Publ. World Fed. Neurol. Res. Group Mot. Neuron Dis.*, 2008, **9**, 177–183.
- 450 22 J. D. Morrow, A. R. Tapper, W. E. Zackert, J. Yang, S. C. Sanchez, T. J. Montine and L. J. Roberts, *Adv. Exp. Med.*  
451 *Biol.*, 1999, **469**, 343–347.
- 452 23 L. J. Roberts and J. D. Morrow, *Free Radic. Biol. Med.*, 2000, **28**, 505–513.
- 453 24 D. Giustarini, I. Dalle-Donne, D. Tsikas and R. Rossi, *Crit. Rev. Clin. Lab. Sci.*, 2009, **46**, 241–281.
- 454 25 G. Ferretti and T. Bacchetti, *J. Neurol. Sci.*, 2011, **311**, 92–97.
- 455 26 S. Basu, *Antioxid. Redox Signal.*, 2008, **10**, 1405–1434.
- 456 27 M. E. M. Peluso, A. Munnia, M. Tarocchi, R. W. Giese, L. Annaratone, G. Bussolati and R. Bono, *Toxicol. Res.*,  
457 2014, **3**, 341–349.
- 458 28 G. Bussolati, L. Chiusa, A. Cimino and G. D'Armento, *Virchows Arch. Int. J. Pathol.*, 2008, **452**, 229–231.
- 459 29 C. Di Novi, D. Minniti, S. Barbaro, M. G. Zampirolo, A. Cimino and G. Bussolati, *Sci. Total Environ.*, 2010, **408**,  
460 3092–3095.
- 461 30 L. Annaratone, C. Marchiò, R. Russo, L. Ciardo, S. M. Rondon-Lagos, M. Goia, M. S. Scalzo, S. Bolla, I.  
462 Castellano, L. Verdun di Cantogno, G. Bussolati and A. Sapino, *PLoS ONE*, 2013, **8**.
- 463 31 R. Bono, V. Romanazzi, A. Munnia, S. Piro, A. Allione, F. Ricceri, S. Guarrera, C. Pignata, G. Matullo, P. Wang, R.  
464 W. Giese and M. Peluso, *Chem. Res. Toxicol.*, 2010, **23**, 1342–1348.
- 465 32 R. Bono, V. Romanazzi, V. Pirro, R. Degan, C. Pignata, E. Suppo, M. Pazzi and M. Vincenti, *Sci. Total Environ.*,  
466 2012, **414**, 701–707.
- 467 33 F. Blum, 1893, 314–315.
- 468 34 G. Bussolati, L. Annaratone, E. Medico, G. D'Armento and A. Sapino, *PLoS One*, 2011, **6**, e21043.
- 469 35 F. Veglia, S. Loft, G. Matullo, M. Peluso, A. Munnia, F. Perera, D. H. Phillips, D. Tang, H. Autrup, O. Raaschou-  
470 Nielsen, A. Tjønneland, P. Vineis and Genair-EPIC Investigators, *Carcinogenesis*, 2008, **29**, 932–936.
- 471
- 472

<b>FA total (number)</b>	Subjects NOT using FA during the sampling day	<b>64</b>			
	Subjects USING FA during the sampling day	<b>30</b>	FA prefilled	<b>12</b>	
			FA liquid	<b>18</b>	
<b>Smoking habits (number)</b>	No smokers	<b>51</b>			
	Passive smokers	<b>20</b>			
	Active smokers	<b>23</b>			
	<b>Yes UVS</b>	<b>No UVS</b>	<b>p</b>		
<i>Total number</i>	<b>38</b>	<b>56</b>	-		
	<b>Means ± sd</b>				
<i>Height (number)</i>	<b>163.1 ± 5.1</b>	<b>162.8 ± 6.1</b>	NS		
<i>Weight (number)</i>	<b>61.9 ± 9.9</b>	<b>66.6 ± 16.4</b>	NS		
<i>BMI</i>	<b>23.3 ± 3.7</b>	<b>25.1 ± 6.0</b>	NS		
<i>Age (years)</i>	<b>45 ± 8.6</b>	<b>46.2 ± 7.6</b>	NS		
	<b>Absolute (%) frequencies</b>				
<i>Smoking habits</i>	No smokers	<b>25 (46%)</b>	No smokers	<b>26 (66%)</b>	
	Passive smokers	<b>6 (25%)</b>	Passive smokers	<b>14 (16%)</b>	
	Active smokers	<b>7 (29%)</b>	Active smokers	<b>16 (18%)</b>	
<i>FA (number)</i>	Subjects using FA	<b>15</b>	Subjects using FA	<b>15</b>	
		Prefilled	5	Prefilled	7
		liquid	10	liquid	8
		Subjects <u>not</u> using FA*	<b>23</b>	Subjects <u>not</u> using FA*	<b>41</b>
				-	

**Table 1.** Number of subjects according to the use of FA and subjects characteristics (means and standard deviations for variables in interval scales and frequencies absolute and % for variables categoricals) subgrouped by vacuum presence. \*on the day of sampling.

Statistical significativity estimated with non parametric statistical tests for two indipent samples  
NS = not significant

		FA ( $\mu\text{g}/\text{m}^3$ )		Non parametric test
		Means $\pm$ sd		
A	Personal air-FA in the population (n=94)	20.7 $\pm$ 23.3		
	Subjects USING FA (n=64)	33.7 $\pm$ 37.9		$p = 0.032$
	Subjects NOT using FA (n=30)	14.6 $\pm$ 4.6		
		UVS	NO UVS	Non parametric test UVS vs NO UVS
B	All the subjects	15.5 $\pm$ 7.4	All the subjects 24.2 $\pm$ 29.1	$p = 0.040$
	Subjects not using FA	12.1 $\pm$ 2.6	Subjects not using FA 16.0 $\pm$ 4.9	$p = 0.002$
C	Subjects using FA	20.7 $\pm$ 9.3	Subjects using FA 46.7 $\pm$ 50.3	$p = 0.001$
	FA prefilled	18.4 $\pm$ 5.4	FA prefilled 25.6 $\pm$ 5.5	<i>N.S.</i>
	FA liquid	20.9 $\pm$ 9.7	FA liquid 65.0 $\pm$ 64.0	$p = 0.001$

**Table 2.** Personal air-FA ( $\mu\text{g}/\text{m}^3$ ) in the whole population (A), quantified according to the availability of UVS in the surgical theatres (B), to the use of FA on the day of sampling (C), and the robust regression between air-FA and use of UVS subgrouped by the type of container of FA (prefilled or large container). C.I. = confidence interval

log FA	Regression coefficient B	exponential exp(B)	Std. err.	<i>p</i>
Prefilled (adj. by UVS)	0.49 [0.32 - 0.67]	1.65	0.08	<b>0.000</b>
Liquid (adj. by UVS)	1.06 [0.83-1.29]	2.90	0.11	<b>0.000</b>
Personal air-FA with UVS	-0.26 [0.38 - -0.12]	0.77	0.06	<b>0.000</b>
Prefilled	-0.15 [-0.60 - 0.30]	0.86	0.22	<i>N.S.</i>
liquid	-0.51 [-0.84 - -0.18]	0.60	0.16	<b>0.003</b>

**Table 3** The robust regression between air-FA and use of UVS end interaction ((\*) between UVS use and the type of container of FA (prefilled or large container). C.I. = confidence interval within square brackets. NB exponentiation of coefficients express the proportion of variation by group.

<b>15-F<sub>2t</sub>-IsoP (ng/mg CREA)</b>				
Subjects USING FA		<b>12.9 ± 6.9</b>		<i>p</i> = 0.001
Subjects NOT using FA		<b>3.8 ± 3.1</b>		
<b>UVS</b>		<b>NO UVS</b>		<i>p</i> = 0.027
<b>6.3 ± 4.5</b>		<b>7.0 ± 7.3</b>		
Subjects using FA	<b>10.1 ± 4.3</b>	Subjects using FA	<b>15.8 ± 8.0</b>	<i>p</i> = 0.029
Subjects NOT using FA	<b>3.7 ± 3.3</b>	Subjects NOT using FA	<b>3.9 ± 2.7</b>	N.S.
FA prefilled	<b>6.4 ± 2.2</b>	FA prefilled	<b>10.9 ± 6.2</b>	N.S.
FA liquid	<b>11.9 ± 3.9</b>	FA liquid	<b>20.1 ± 7.1</b>	0.012
<b>MDA (µM)</b>				
Subjects using FA		<b>1.9 ± 0.7</b>		N.S.
Subjects not using FA		<b>1.2 ± 0.6</b>		
<b>UVS</b>		<b>NO UVS</b>		N.S.
<b>1.3 ± 0.8</b>		<b>1.5 ± 0.6</b>		
Subjects using FA	<b>1.7 ± 0.5</b>	Subjects using FA	<b>2.1 ± 0.9</b>	N.S.
Subjects NOT using FA	<b>1.1 ± 0.5</b>	Subjects NOT using FA	<b>1.3 ± 0.6</b>	N.S.
FA prefilled	<b>1.4 ± 0.3</b>	FA prefilled	<b>1.5 ± 0.2</b>	N.S.
FA liquid	<b>1.8 ± 0.4</b>	FA liquid	<b>2.6 ± 0.9</b>	<i>p</i> = 0.012
<b>Cotinine (ng/mg CREA)</b>				
The whole population		<b>32.8 ± 59.5</b>		<i>p</i> = 0.035
No smokers		<b>3.1 ± 2.0</b>		
Passive smokers		<b>6.2 ± 10.7</b>		
Active smokers		<b>109.0 ± 68.2</b>		
Subjects using FA		<b>28.9 ± 61.8</b>		N.S.
Subjects not using FA		<b>34.1 ± 58.8</b>		

**Table 4.** 15-F<sub>2t</sub>-Isop, MDA and cotinine subgrouped according the UVS availability, use of FA and smoking exposure (CREA = creatinine). The models were adjusted by age, gender, BMI and cotinine.

independent	Regression coefficient B	Esponential exp (B)	p
<b>log [MDA]</b>	0.77 [0.38 - 1.17]	2.18	<b>0.002</b>
<b>Costant</b>	-2.04 [-3.04 - -1.05]	.13	
<b>log [15-F<sub>2t</sub>-IsoP]</b>	1.02 [0.66 - 1.38]	2.78	<b>0.001</b>
<b>Costant</b>	-1.45 [-2.64 - -2.47]	.23	

**Table 5.** Robust regression between log-15-F<sub>2t</sub>-IsoP and MDA as dependent variables and log-FA as independent variable. UVS, cotinine, and age effect were not significant at 5% level. C.I. = confidence interval

NB exponentiation of coefficients express the proportion of variation for unit of variation of log(FA)

